Artal Group’s Spero Therapeutics SPRO Stock Holding History

Artal Group’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-500,000	Closed	-$1M	–	135
2022 Q3	$1M	Hold	500,000	–	–	0.04%	114
2022 Q2	$371K	Hold	500,000	–	–	0.02%	130
2022 Q1	$4.35M	Hold	500,000	–	–	0.18%	86
2021 Q4	$8.01M	Hold	500,000	–	–	0.22%	79
2021 Q3	$9.21M	Hold	500,000	–	–	0.21%	83
2021 Q2	$6.98M	Hold	500,000	–	–	0.14%	111
2021 Q1	$7.36M	Hold	500,000	–	–	0.13%	114
2020 Q4	$9.7M	Sell	500,000 -100,000	-17%	-$1.56M	0.21%	88
2020 Q3	$6.7M	Buy	600,000 +54,960	+10%	+$650K	0.16%	88
2020 Q2	$7.37M	Sell	545,040 -30,960	-5%	-$348K	0.21%	86
2020 Q1	$4.65M	Buy	576,000 +76,000	+15%	+$670K	0.2%	75
2019 Q4	$4.81M	Sell	500,000 -40,000	-7%	-$431K	0.19%	74
2019 Q3	$5.72M	Hold	540,000	–	–	0.23%	69
2019 Q2	$6.21M	Sell	540,000 -60,000	-10%	-$722K	0.25%	71
2019 Q1	$7.69M	Hold	600,000	–	–	0.31%	63
2018 Q4	$3.69M	Hold	600,000	–	–	0.14%	76
2018 Q3	$6.31M	Buy	600,000 +250,000	+71%	+$2.9M	0.16%	67
2018 Q2	$5.13M	Hold	350,000	–	–	0.11%	67
2018 Q1	$4.99M	Hold	350,000	–	–	0.06%	70
2017 Q4	$4.11M	Buy	+350,000	New	+$4.3M	0.06%	77

Other funds holding SPRO

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group's SPRO Position: Q4 2022 in Review

Artal Group sold out of Spero Therapeutics (SPRO) in Q4 2022, closing a stake of 500,000 shares — an estimated $1M sold.

Artal Group first reported a position in SPRO in Q4 2017 and held it in 20 quarters. The position peaked at $9.7M in Q4 2020. 60 funds tracked by Wall St. Rank hold SPRO as of Q4 2022.

Artal Group reported no remaining Spero Therapeutics position as of Q4 2022 after selling out during the quarter.
Artal Group sold 500,000 Spero Therapeutics shares in Q4 2022, an estimated $1M.
Artal Group first reported a position in Spero Therapeutics in Q4 2017 and held it in 20 quarters.
Artal Group's Spero Therapeutics position peaked at $9.7M in Q4 2020.
60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2022.

Based on Artal Group's 13F filing for Q4 2022, filed 13 Feb 2023.